Insider · CIK 0001401018

Patterson Matthew R

Reports to the SEC for 5 companies · CRANBURY, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001401018

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-05-22	VORVor Biopharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2024-05-23	VORVor Biopharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-06-14	QTTBQ32 Bio Inc. · Option (Right to Buy)A Award	Director	AAward	+23K sh	—	—	23,000
2023-05-26	VORVor Biopharma Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2022-06-15	QTTBQ32 Bio Inc. · Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2022-06-14	VORVor Biopharma Inc. · Stock Option (right to buy)A Award	Director	AAward	+16.9K sh	—	—	16,911
2021-06-17	QTTBQ32 Bio Inc. · Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2021-02-05	VORVor Biopharma Inc. · Stock Option (right to buy)A Award	Director	AAward	+16.9K sh	—	—	16,900
2020-10-16	5:01 Acquisition Corp.Class B Common StockJ Other	Director	JOther	+30K sh	—	—	30,000
2020-06-10	QTTBQ32 Bio Inc. · Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−177K sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−225K sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−172K sh	$60.00	−$10.3M	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−144K sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−261K sh	$60.00	−$15.7M	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−188K sh	—	—	0
2020-01-08	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−11.7K sh	—	—	188,334
2020-01-08	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−11.8K sh	—	—	143,569
2020-01-08	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−74.3K sh	—	—	0
2020-01-08	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−64.8K sh	—	—	0
2020-01-08	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+11.7K sh	$15.26	+$178K	261,458
2020-01-08	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+74.3K sh	$2.19	+$163K	237,968
2020-01-08	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+64.8K sh	$0.78	+$50.5K	163,671
2020-01-08	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+11.8K sh	$9.50	+$112K	249,792
2019-12-26	Audentes Therapeutics, Inc.G Gift	Director, Chief Executive Officer	GGift	−12.5K sh	—	—	98,920
2019-12-05	Audentes Therapeutics, Inc.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−1,974 sh	$59.21	−$117K	111,420
2019-11-08	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.4K sh	—	—	155,393
2019-11-08	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−14.4K sh	$30.00	−$433K	113,394
2019-11-08	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+14.4K sh	$9.50	+$137K	127,820
2019-09-05	Audentes Therapeutics, Inc.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−1,974 sh	$31.02	−$61.2K	113,394
2019-08-12	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−19K sh	$34.02	−$646K	116,368
2019-08-12	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,000 sh	$34.52	−$34.5K	115,368
2019-08-12	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−20K sh	—	—	169,819
2019-08-12	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+20K sh	$9.50	+$190K	135,368
2019-06-06	QTTBQ32 Bio Inc. · Option (Right to Buy)A Award	Director	AAward	+15.6K sh	—	—	15,580
2019-06-05	Audentes Therapeutics, Inc.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−3,332 sh	$37.31	−$124K	115,368
2019-02-25	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−4,000 sh	$30.00	−$120K	118,700
2019-02-25	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−17K sh	—	—	64,751
2019-02-25	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+4,000 sh	$2.19	+$8,760	122,700
2019-02-25	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−4,000 sh	—	—	74,297
2019-02-25	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+17K sh	$0.78	+$13.3K	135,700
2019-02-25	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−17K sh	$30.00	−$510K	118,700
2019-02-06	Audentes Therapeutics, Inc.Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+177K sh	—	—	177,450
2019-02-06	Audentes Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+63.7K sh	—	—	118,700
2018-12-06	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−40K sh	—	—	31,702
2018-12-06	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+40K sh	$0.78	+$31.2K	55,000
2018-10-01	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−8,078 sh	$37.70	−$305K	15,000
2018-10-01	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−21K sh	—	—	71,702
2018-10-01	Audentes Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+2,144 sh	$0.78	+$1,672.32	17,144
2018-10-01	Audentes Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,144 sh	$39.13	−$83.9K	15,000

Recent filings

Accepted (ET)
May 234
Patterson Matthew R0001415889-25-014527
SEC(opens sec.gov)
May 284
Patterson Matthew R0001415889-24-014647
SEC(opens sec.gov)
Jun 154
Patterson Matthew R0000950170-23-028411
SEC(opens sec.gov)
Jun 24
Patterson Matthew R0001209191-23-033818
SEC(opens sec.gov)
Jun 174
Patterson Matthew R0000899243-22-023069
SEC(opens sec.gov)
Jun 164
Patterson Matthew R0001209191-22-037519
SEC(opens sec.gov)
Jun 224
Patterson Matthew R0000899243-21-025333
SEC(opens sec.gov)
Feb 94
Patterson Matthew R0001209191-21-008891
SEC(opens sec.gov)
Oct 204
Patterson Matthew R0001209191-20-055443
SEC(opens sec.gov)
Jun 124
Patterson Matthew R0000899243-20-016390
SEC(opens sec.gov)
Jan 154
Patterson Matthew R0001209191-20-003434
SEC(opens sec.gov)
Jan 104
Patterson Matthew R0001209191-20-003110
SEC(opens sec.gov)

Companies

Address

C/O AMICUS THERAPEUTICS, INC. 6 CEDAR BROOK DRIVE

CRANBURY, NJ, 08512